Autopsy report · NCT03494231

A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors

“Lack of efficacy”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 2 months before it stopped.
• 5 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Henlix, Inc

Sponsor type

Industry

Conditions

Solid Tumor, Adult

Interventions

HLX06

Participants

5

Sites

1

Countries

Taiwan

Trials that died the same way

• Cross Linking for Treatment of Corneal Infection
  “insufficient efficacy” (91% match in meaning)
• Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis
  “lack of efficacy and lack of funding” (85% match in meaning)
• Influence of Esmolol on a Closed-Loop Anesthesia System
  “lack of effectiveness” (81% match in meaning)
• Efficacy of the Infusion of Donor Plasma in COVID-19 Infection
  “Lack of efficacy of treatment tested” (77% match in meaning)
• Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
  “Lack of efficacy. Stopped at first interim evaluation point” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.